scholarly journals Effect of Trimethyl Chitosan with Different Degrees of Quaternization on the Properties of Tablets Prepared using Charged Model Drugs

2021 ◽  
Vol 18 (10) ◽  
Author(s):  
Supavadee BOONTHA ◽  
Duangdau JAICHUM ◽  
Kannikar KUNSEANG ◽  
Korrakrit WANJAI ◽  
Worawan BOONYO ◽  
...  
Keyword(s):  
Drug Release ◽  
Intrinsic Viscosity ◽  
The United States ◽  
Dissolution Profile ◽  
Polymer Backbone ◽  
Trimethyl Chitosan ◽  
Weight Variation ◽  
Tablet Formulations ◽  
Charged Model ◽  
Positively Charged

Trimethyl chitosan (TMC) has demonstrated effectiveness as an absorption enhancer for hydrophilic and high molecular weight (MW) drugs across the intestinal epithelium. However, the effects of degrees of quaternization (DQ) of TMC on the absorption of negatively and positively charged drugs have not been investigated. This investigation aimed to determine the properties of the tablets formulated using TMC with different DQ. In this study, TMC with DQ of 20 % (TMC-20), 40 % (TMC-40) and 60 % (TMC-60) were synthesized and subsequently characterized. Cetirizine dihydrochloride (CHC) and hyoscine butylbromide (HBB) were used as negatively and positively charged model drugs. Eight tablet formulations were prepared using the wet granulation method. The formulated tablets were evaluated regarding their properties in terms of thickness and hardness, weight variation, disintegration time, and dissolution profile. These tablets were evaluated according to the standards set by the United States Pharmacopeia (USP41) guidelines. The results showed that TMC with all DQ have the MW and an intrinsic viscosity less than starting chitosan. The MW and an intrinsic viscosity of the synthesized TMC decreased with increasing DQ. In order to evaluate the effect of TMC with various DQ on the properties of the formulated tablets, all tablet formulations prepared had good characteristics and were found to be within the acceptable range based on the requirements of USP. In conclusion, TMC had a minor retarding effect on the dissolution profiles of CHC from the formulated tablets. Still, TMC was able to significantly delay the release of HBB from the formulated tablets (p > 0.05). When TMC with various DQ were compared, TMC-60 showed higher drug release than TMC-20 and TMC-40.  In our study, we observed a possible interaction between the model drugs and TMC. This warrants the need for further studies. HIGHLIGHTS Degree of quaternization represents the charge density of trimethyl chitosan (TMC)  Degradation of the polymer backbone occurred in the synthesis reaction step   TMC affects dissolution profiles of a negative charged drug  Ionic interaction and viscous gel layer of TMC affects the model drug release 

Effects of release modifier on Carvedilol release from Kollidon SR based matrix

2012 ◽  
Vol 1 (8) ◽  
pp. 186 ◽  
Author(s):  
Urmi Das ◽  
Mohammad Salim Hossain
Keyword(s):  
Drug Release ◽  
Sustained Release ◽  
Microcrystalline Cellulose ◽  
Matrix Tablets ◽  
Dissolution Time ◽  
Release Mechanism ◽  
Matrix Tablet ◽  
Weight Variation ◽  
The Matrix ◽  
Tablet Formulations

<p>Sustained release Carvedilol matrix tablets constituting Kollidon SR were developed in this study in an attempt to investigate the effect of release modifiers on the release profile of Carvedilol from matrix. Three matrix tablet formulations were prepared by direct compression of Kollidon SR in combination with release modifier (HPMC and Microcrystalline Cellulose) and magnesium stearate. Tablets containing only Kollidon SR with the active ingredient demonstrated a rapid rate of drug release. Incorporation of HPMC in the matrix tablet prolonged the release of drug but incorporation of Microcrystalline Cellulose showed superimposable release pattern with an initial burst effect as confirmed by mean dissolution time and Higuchi release rate data. After 7 hours of dissolution, Carvedilol release from the matrix systems were 91.42%, 83.41%, from formulation F1 and F2 respectively. Formulation F3 exhibited 100 % release at 4 hours. All the tablet formulations showed acceptable pharmaco-technical properties and complied with the in-house specifications for tablet weight variation, friability, hardness, thickness, and diameter. Prepared tablets also showed sustained release property for carvedilol. The drug release mechanism from the matrix tablets of F1 and F2 was found to be followed by Fickian and F3 by Non-Fickian mechanism.</p><p>DOI: <a href="http://dx.doi.org/10.3329/icpj.v1i8.11095">http://dx.doi.org/10.3329/icpj.v1i8.11095</a></p> <p>International Current Pharmaceutical Journal 2012, 1(8): 186-192</p>

Utilization of a Single Experimental Design for the Optimization of Furosemide Modified-Release Tablet Formulations

2019 ◽  
Vol 16 (10) ◽  
pp. 931-939
Author(s):  
Marilena Vlachou ◽  
Angeliki Siamidi ◽  
Yannis Dotsikas
Keyword(s):  
Experimental Design ◽  
Drug Release ◽  
Burst Release ◽  
Dissolution Profile ◽  
Modified Release ◽  
Lactose Monohydrate ◽  
Bilayer Tablets ◽  
Combined Design ◽  
Tablet Formulations ◽  
Optimal Combined Design

Background: The loop diuretic drug furosemide is widely used for the treatment of edema in various conditions, such as pulmonary, cardiac and hepatic edema, as well as cardiac infarction. Furosemide, due to its poor water solubility and low bioavailability after oral administration of conventional dosage form, is categorized as class IV in the biopharmaceutical classification system. Objective: In the case of furosemide, this release profile is responsible for various physiological problems, acute diuresis being the most serious. This adverse effect can be circumvented by the modified release of furosemide from tablet formulations compared to those forms designed for immediate release. Method: In this report, a D-optimal combined experimental design was applied for the development of furosemide containing bilayer and compression coated tablets, aiming at lowering the drug’s burst release in the acidic environment of the stomach. A D-optimal combined design was selected in order to include all requirements in one design with many levels for the factors examined. The following responses were selected as the ones reflecting better criteria for the desired drug release: dissolution at 120 min (30-40%), 300 min (60-70%) and 480 min >95%. The new formulations, suggested by the Doptimal combined design, incorporated different grades of Eudragit ® polymers (Eudragit® E100 and Eudragit® L100-55), lactose monohydrate and HPMC K15M. The dissolution profile of furosemide from these systems was probed via in vitro dissolution experiments in buffer solutions simulating the pH of the gastrointestinal tract. Results: The results indicate that the use of Eudragit® E100 in conjunction with lactose monohydrate led to 21.32-40.85 % drug release, in the gastric medium, in both compression-coated and bilayer tablets. This is lower than the release of the mainstream drug Lasix® (t=120 min, 44.5% drug release), implying longer gastric retention and drug waste minimization. Conclusion: Furosemide’s release in the intestinal environment, from compression coated tablets incorporating Eudragit® L100-55 and HPMC K15M in the inner core or one of the two layers of the bilayer tablets, was delayed, compared to Lasix®

scholarly journals Eight enteric-coated 50 mg diclofenac sodium tablet formulations marketed in Saudi Arabia: in vitro quality evaluation

2020 ◽  
Vol 13 (1) ◽  
Author(s):  
Muhammad M. Hammami ◽  
Rajaa F. Hussein ◽  
Reem AlSwayeh ◽  
Syed N. Alvi
Keyword(s):  
Quality Evaluation ◽  
Diclofenac Sodium ◽  
Dissolution Profile ◽  
Disintegration Time ◽  
United States Pharmacopoeia ◽  
Weight Variation ◽  
Tablet Formulations ◽  
Enteric Coated

Abstract Objective To evaluate in vitro quality of enteric-coated 50 mg diclofenac sodium tablet formulations on Saudi market. Results A reference and seven generic (G1-7) formulations were commercially available in December 2019/January 2020 and were assessed within 25–75% of manufacture-expiration period. Weight variation (range as% difference from mean, n = 20), active substance content (ASC, mean (SD) as% difference from label, n = 20), hardness (mean (SD), n = 10), and friability (% weight loss, n = 20) were 97–103%, 102.0% (3.4%), 15.4 (1.1) kg, and 0.24%, respectively, for the reference. For G2-7, they were ≤ ±5%, 98.6% (4.0%) to 109.9% (1.8%), 11.9 (0.9) to 18.3 (0.8) kg, and ≤ 0.00 to 0.75%, respectively. G1 ASC, hardness, and friability were 111.3% (1.7%), 20.1 (1.7) kg, and 1.10%, respectively. Disintegration time (n = 6) and dissolution profile (n = 8) were also determined. No formulation disintegrated or released ˃ 0.1% of label ASC in 0.1 N HCl for 2 h. The reference disintegrated in 15:00 min:seconds and released a mean (range) of 100% (99–103%) of label ASC by 45 min in phosphate buffer (pH = 6.8). G1-7 disintegrated in 8:53 to 20:37 min:seconds and released 81% (69–90%) (G1) to 109%. Except for borderline performance of G1, all formulations passed in vitro quality tests according to United States Pharmacopoeia.

Formulation and Evaluation of the Sustained Release Tablet of Ketorolac Tromethamine Using Natural Polymer as an Extended Releasing Agent

2017 ◽  
Vol 9 (08) ◽  
Author(s):  
Gadhave M. V. ◽  
Deokar Rutuja V. ◽  
Jadhav S. L. ◽  
Gaikwad D. D.
Keyword(s):  
Drug Release ◽  
Sustained Release ◽  
In Vitro Release ◽  
Aloe Vera ◽  
Phosphate Buffer Solution ◽  
Angle Of Repose ◽  
Dissolution Profile ◽  
Ketorolac Tromethamine ◽  
Weight Variation ◽  
Aloe Vera Gel

Sustained release tablets of Ketorolac Tromethamine were formulated using Aloe vera Gel Powder as extended drug releasing agent. The tablets were evaluated for preformulation studies like angle of repose, bulk density, compressibility index and physical characteristics like hardness, weight variation, friability and drug content. In-vitro release of drug was carried out in phosphate buffer solution pH 6.8 for twelve hours. All the physical characters of the formulated tablet were found within the acceptable limit. The tablet with Aloe Vera gel powder in Batch-F3 exhibited greater drug release than other batches. It is proved from the dissolution profile of Ketorolac Tromethamine, that Aloe Vera gel powder possess the drug release retarding ability.

DEVELOPMENT AND CHARACTERIZATION OF NOVEL GASTRORETENTIVE RAFT FORMING FLOATING FILM OF ATENOLOL

INDIAN DRUGS ◽  
2015 ◽  
Vol 52 (03) ◽  
pp. 15-23
Author(s):  
N Sharma ◽  
◽  
R. Awasthi
Keyword(s):  
Drug Release ◽  
Polymer Matrix ◽  
Processing Parameters ◽  
Dissolution Profile ◽  
X Ray Diffraction ◽  
Casting Technique ◽  
Floating Raft ◽  
Weight Variation ◽  
Folding Endurance

The aim of present work was to develop a gastroretentive floating raft forming film of atenolol using solvent casting technique. The films were characterized in terms of drug-excipient compatibility by FTIR, drug content, swelling, folding endurance, thermal behaviour by DSC, effect of processing parameters on drug state (amorphous or crystalline) by X-ray diffraction (XRD), and in vitro drug release profiles. The results confirm that there was no interaction between the drug-polymers and fusion of drug crystals within the polymer matrix. Results of XRD indicate partial dissolution of drug within the polymer matrix and suggested it was partly distributed in amorphous form throughout the film. The weight variation, thickness and folding endurance of films were in the range of 2.170 ± 0.05 to 2.444 ± 0.23 gm, 1.120 ± 0.032 to 1.125 ± 0.011 mm and 200 ± 5 to 400 ± 5, respectively. The pH values of the different films were between 6.8 to 7.21. After 24 h, the best selected film shows 75% and 90% of drug release in 0.1 N HCl (pH 1.2) and in phosphate buffer (pH 6.8), respectively. Based on these results it is suggested that the incorporation of drug into the hydrophilic floating film may be an appropriate strategy to improve the dissolution profile and oral bioavailability of the drug.

Theoritical Uses of Pramipexole dihydrochloride in Parkinson's Resistance Depression

2017 ◽  
Vol 1 (2) ◽  
pp. 01-03
Author(s):  
Samuel Langhorne
Keyword(s):  
Drug Release ◽  
Dopamine D2 Receptor ◽  
In Vitro Dissolution ◽  
Molecular Formula ◽  
Dissolution Profile ◽  
Drug Release Profile ◽  
In Vitro Drug Release ◽  
Weight Variation ◽  
Pramipexole Dihydrochloride

Pramipexole dihydrochloride monohydrate is an antiparkinson’s agent which is known as dopamine D2 receptor agonist. It is structurally different from the ergot-derived drugs, e.g. bromocriptine or pergolide. Pramipexole is designated chemically as (S)-2-Amino-4, 5, 6, and 7-tetrahydro-6-(propylamino) benzothiazole and has the molecular formula C10H17N3S. It comes under class I of Biopharmaceutical Classification System. The purpose of this study was to develop and evaluate pramipexole dihydrochloride monohydrate extended release tablets by wet granulation method using different proportions of polymers and binder. Pre-formulation studies were done initially and the results were found to be within the limits. All the mentioned batches were prepared and granules were evaluated for pre-compression parameters such as loss on drying, bulk density, tapped density and compressibility index. Tablets were evaluated for weight variation, thickness, hardness, friability; disintegration time and assay were found to be within the limits. In vitro dissolutions were performed with 0.05M 6.8 PH phosphate buffer and effect of various polymers were explored. Final selection of formulation was based on dissolution profile, from dissolution studies formulation 9 showed 80% drug release within 20 hours, so it will be compared with innovator. Similarity and difference factors which revealed that formulation (F 9) containing HPMC K 200, Eudragit L100 and binder are most successful as it exhibited in vitro drug release that matched with innovator product. In vitro drug release profile reveals that with increased concentration of Eudragit L 100. Accelerated stability studies were performed for the optimized batch which indicated that there were no changes in drug content and in vitro dissolution.

scholarly journals Production of Itraconazole Nanocrystal-Based Polymeric Film Formulations for Immediate Drug Release

Pharmaceutics ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 960
Author(s):  
Anna Karagianni ◽  
Leena Peltonen
Keyword(s):  
Drug Release ◽  
Physicochemical Characterization ◽  
Methyl Cellulose ◽  
Immediate Release ◽  
Polymeric Film ◽  
Content Uniformity ◽  
Dissolution Profile ◽  
Disintegration Time ◽  
Weight Variation ◽  
Film Forming

In order to improve the solubility properties of BCS class II drug itraconazole, fast dissolving oral polymeric film formulations based on itraconazole nanocrystals were produced. Drug nanocrystals were manufactured by the wet pearl milling technique. In polymeric film formulations, hydroxypropyl methyl cellulose (HPMC) was used as a film forming polymer, and glycerin was used as a plasticizer. For nanocrystal suspensions and film formulations, thorough physicochemical characterization was performed, including particle sizing and size deviation, film appearance, weight variation, thickness, folding endurance, drug content uniformity, disintegration time, and dissolution profile. After milling, the nanoparticles were 369 nm in size with a PI value of 0.20. Nanoparticles were stable and after redispersion from film formulations, the particle size remained almost the same (330 nm and PI 0.16). The produced films were flexible, homogeneous, fast disintegrating, and drug release rate from both the nanosuspension and film formulations showed immediate release behavior. Based on the study, the film casting method for production of itraconazole nanocrystal based immediate release formulations is a good option for improved solubility.

scholarly journals Quality analysis of different marketed brands of paracetamol available in Bangladesh

2015 ◽  
Vol 4 (9) ◽  
pp. 432-435
Author(s):  
Auditi Kar ◽  
Mohammad Nurul Amin ◽  
Mohammad Salim Hossain ◽  
Md. Emdadul Hasan Mukul ◽  
Md. Saif Uddin Rashed ◽  
...  
Keyword(s):  
Pharmaceutical Journal ◽  
Quality Analysis ◽  
Dissolution Profile ◽  
Disintegration Time ◽  
Weight Variation ◽  
Tablet Formulations ◽  
Almost All ◽  
Tablet Hardness ◽  
Standard Techniques

Paracetamol is a widely used analgesic and antipyretic drug worldwide. The present study was conducted to analyze the quality of seven marketed brands of paracetamol tablet formulation manufactured by different multinational and national companies. The tablet formulations of different brands were tested for various parameters like weight variation, hardness, friability, disintegration time and dissolution profile using standard techniques to evaluate their quality. The values were compared with the standards. Weight variation value requirement was complied by all brands. All studied samples except two local products complied with the standard specification for tablet hardness. All brands showed impressive friability values and products of multinational companies comparatively exhibited the highest values. Disintegration time for all brands was within 15 minutes also complying the USP (United State of Pharmacopeia) recommendation. Moreover, the release rate of different brands of paracetamol was satisfactory within 45 minutes and ranged from 79.82% to 103.53%. Therefore, it can be concluded that almost all the brands of paracetamol that are available in Bangladesh meet the USP specification for quality control analysis.Kar et al., International Current Pharmaceutical Journal, August 2015, 4(9): 432-435

scholarly journals Synthesis and Evaluation of Thiol-Conjugated Poloxamer and Its Pharmaceutical Applications

Pharmaceutics ◽  
2021 ◽  
Vol 13 (5) ◽  
pp. 693
Author(s):  
Muhammad Zaman ◽  
Sadaf Saeed ◽  
Rabia Imtiaz Bajwa ◽  
Muhammad Shafeeq Ur Rahman ◽  
Saeed Ur Rahman ◽  
...  
Keyword(s):  
Drug Release ◽  
Albino Rats ◽  
Dissolution Profile ◽  
Disintegration Time ◽  
In Vitro Drug Release ◽  
Weight Variation ◽  
Amorphous Nature ◽  
Considerable Concentration

The current study was designed to convert the poloxamer (PLX) into thiolated poloxamer (TPLX), followed by its physicochemical, biocompatibilities studies, and applications as a pharmaceutical excipient in the development of tacrolimus (TCM)-containing compressed tablets. Thiolation was accomplished by using thiourea as a thiol donor and hydrochloric acid (HCl) as a catalyst in the reaction. Both PLX and TPLX were evaluated for surface morphology based on SEM, the crystalline or amorphous nature of the particles, thiol contents, micromeritics, FTIR, and biocompatibility studies in albino rats. Furthermore, the polymers were used in the development of compressed tablets. Later, they were also characterized for thickness, diameter, hardness, weight variation, swelling index, disintegration time, mucoadhesion, and in vitro drug release. The outcomes of the study showed that the thiolation process was accomplished successfully, which was confirmed by FTIR, where a characteristic peak was noticed at 2695.9968 cm−1 in the FTIR scan of TPLX. Furthermore, the considerable concentration of the thiol constituents (20.625 µg/g of the polymer), which was present on the polymeric backbone, also strengthened the claim of successful thiolation. A mucoadhesion test illustrated the comparatively better mucoadhesion strength of TPLX compared to PLX. The in vitro drug release study exhibited that the TPLX-based formulation showed a more rapid (p < 0.05) release of the drug in 1 h compared to the PLX-based formulation. The in vivo toxicity studies confirmed that both PLX and TPLX were safe when they were administered to the albino rats. Conclusively, the thiolation of PLX made not only the polymer more mucoadhesive but also capable of improving the dissolution profile of TCM.

scholarly journals Effects of release modifier on Carvedilol release from Kollidon SR based matrix

2012 ◽  
Vol 1 (8) ◽  
pp. 186-192 ◽  
Author(s):  
Urmi Das ◽  
Mohammad Salim Hossain
Keyword(s):  
Drug Release ◽  
Sustained Release ◽  
Microcrystalline Cellulose ◽  
Matrix Tablets ◽  
Dissolution Time ◽  
Release Mechanism ◽  
Matrix Tablet ◽  
Weight Variation ◽  
The Matrix ◽  
Tablet Formulations

Sustained release Carvedilol matrix tablets constituting Kollidon SR were developed in this study in an attempt to investigate the effect of release modifiers on the release profile of Carvedilol from matrix. Three matrix tablet formulations were prepared by direct compression of Kollidon SR in combination with release modifier (HPMC and Microcrystalline Cellulose) and magnesium stearate. Tablets containing only Kollidon SR with the active ingredient demonstrated a rapid rate of drug release. Incorporation of HPMC in the matrix tablet prolonged the release of drug but incorporation of Microcrystalline Cellulose showed superimposable release pattern with an initial burst effect as confirmed by mean dissolution time and Higuchi release rate data. After 7 hours of dissolution, Carvedilol release from the matrix systems were 91.42%, 83.41%, from formulation F1 and F2 respectively. Formulation F3 exhibited 100 % release at 4 hours. All the tablet formulations showed acceptable pharmaco-technical properties and complied with the in-house specifications for tablet weight variation, friability, hardness, thickness, and diameter. Prepared tablets also showed sustained release property for carvedilol. The drug release mechanism from the matrix tablets of F1 and F2 was found to be followed by Fickian and F3 by Non-Fickian mechanism.DOI: http://dx.doi.org/10.3329/icpj.v1i8.11248 International Current Pharmaceutical Journal 2012, 1(8): 186-192 

Sign in / Sign up

Export Citation Format

Share Document